IPCA labs


#68

anyone attended conf call today? what is the status of resolving usfda issues


(Jalal Funds) #69

There are some Con. Call highlights mentioned on ICICI Research Report dated 09/02/2018.

Conference call Highlights

 IPCA management has guided EBITDA margins at 18-18.5% in
FY19
 YoY anti-malarial segment has reduced to 8% of the domestic
portfolio, whereas pain segment has improved to 44%, followed
by Cardio segment at 21%, thereby lowering the portfolio from
historical anti-malarial volatility in sales (earlier anti-malarial
contribution was at 13%)
 On the generic exports segment, UK sales continued to remain
subdued. However, higher Canadian sales led by increased
product launches, strong 46% EU growth and 15% Australia and
New Zealand growth led to higher generic exports segments
growth. The management continues to remain positive on the
above segment and expects the UK sales to rebound in FY19
 On the Institutional exports segment, the management expects
the WHO anti-malarial tender to kick start from Q1FY19. The
management expects DT business to begin in H2FY19 and
injectables launch in H2FY20
 On the branded business, the management expects to grow at 20-
25% in FY19
 US total cumulative filings stood at 47, of which 18 are approved
 Health Canada has successfully inspected all 3 of IPCAs facilities
during the quarter
 The management expects stable CRAMs numbers from H2FY20
 The management has guided for effective tax rate at ~17-18% for
FY19
 The management expects capex for FY19 at similar levels to FY18
i.e. 130-140 crore
 The company has completed remediation at its three facilities and
has invited USFDA officials for inspection

For full report you can check below link

http://content.icicidirect.com/mailimages/IDirect_IpcaLabs_Q3FY18.pdf